Oppenheimer downgraded Vertex Pharmaceuticals (VRTX) to Perform from Outperform without a price target after the company announced results from ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with ...

Vertex stock plummeted Thursday after the company's non-opioid pain drug proved it's no better than a placebo in patients ...

Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...

Patients with chronic pain treated with the novel Fast-Acting Sub-Perception Therapy (FAST) spinal cord stimulation (SCS) ...

Curious if you fall into the lower middle class? Many of us wonder where we stand financially, and it’s not always easy to tell. This socio-economic group is often misunderstood, with many thinking it ...

A lengthy list of deductions remains available to lower taxable income for full- or part-time self-employed taxpayers. Maximizing retirement savings is one of the most straightforward ways to ...

Back pain can result from injury, activity, and some medical conditions. It can affect people of any age and for different reasons. As people get older, the likelihood of developing lower back ...